Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
Cervical Cancer|Genital Warts
BIOLOGICAL: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3, Seroconversion is defined as going from seronegative to seropositive.

Seropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL)., Week 4 Postdose 3 (Month 7)|Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3, Week 4 Postdose 3 (Month 7)|Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3, Seroconversion is defined as going from seronegative to seropositive.

Seropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL)., Week 4 Postdose 3 (Month 7)|Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3, Week 4 Postdose 3 (Month 7)|Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3, Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL). Seroconversion is defined as going from seronegative to seropositive., Week 4 Postdose 3 (Month 7)|Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3, Week 4 Postdose 3 (Month 7)|Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3, Seroconversion is defined as going from seronegative to seropositive.

Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL)., Week 4 Postdose 3 (Month 7)|Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3, Seroconversion is defined as going from seronegative to seropositive.

Seropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL)., Week 4 Postdose 3 (Month 7)|Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3, Week 4 Postdose 3 (Month 7)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.